Johnson & Johnson Innovation, an investment subsidiary of US-based pharmaceutical company Johnson & Johnson, launched a European incubator initiative called JLinx on Wednesday.
Johnson & Johnson and pharmaceutical research subsidiary Janssen Pharmaceuticals will partner for the program, which will be run from a dedicated facility on the Janssen campus in Beerse, Belgium.
Jlinx, which is affiliated with the recent launch of Janssen Human Microbiome Institute, will focus on microbiome research as well as other pharmaceutical and healthcare sectors. It has received its initial funding from Johnson & Johnson Innovation – JJDC with plans to add external investors in future.
Venture capital firm Bioqube Ventures will run the incubator’s day-to-day operations, manage investor relations and funding levels, and help with company selection.
Jlinx has begun accepting applications with plans to be live by summer 2016. Successful applicants will be given access to investment and infrastructure, as well as internal and external scientific, technical and business expertise.